Annals of the Rheumatic Diseases
Издатель: Elsevier · ISSN 0003-4967 · 86 статей
- Sustained improvement of systemic lupus erythematosus‑associated pulmonary arterial hypertension by CD19 CAR T-cell therapy: 1‑year haemodynamic follow‑up
- Type I interferon activation in classical monocytes and GZMK+ CD8+ T cells characterises the ultrasound-negative phase of imminent rheumatoid arthritis
- Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment
- Ten rules to reduce noise and increase precision in imaging studies in rheumatology: a methodological viewpoint informed by narrative reviews
- Medicalising the Human Cell Atlas for musculoskeletal disease: towards a translational roadmap
- Kidney spatial multiomics mapping decodes scleroderma renal crisis
- A CCL20+ macrophage subpopulation is the major producer of TNF in axial spondyloarthritis synovium and is driven by CD40L and a myeloid autocrine circuit
- International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica
- Real‑world assessment of the effectiveness and response profiles of biologic DMARDs in psoriatic arthritis: findings from an emulated multicentre clinical trial
- Performance of MRI-based synthetic CT for detecting spinal new bone formation in patients with inflammatory arthritis and healthy controls: a comparison with MRI, CT, and radiography
- Practical recommendations for revaccination following BCMA-targeted therapies in adult patients with autoimmune diseases
- Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study
- Rescue therapy of paediatric lupus nephritis with plasma cell-directed antibodies
- Mosunetuzumab as salvage therapy for refractory connective tissue diseases: clinical responses and immunological insights
- Proinflammatory strains of Mediterraneibacter gnavus are enriched during spondyloarthritis and bolster disease severity in animal model
- Spatial transcriptomics in immune-mediated necrotising myopathy uncovers a specific necrotic signature related to immune-driven fibrosis
- Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project
- Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design
- Ultrasound-defined presynovitis is associated with progression to clinical arthritis in ACPA-positive individuals at risk of rheumatoid arthritis: longitudinal insights from the Karolinska Risk-RA cohort
- A global OMERACT ultrasound joint damage scoring system (GLODS) in rheumatoid arthritis
- Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- Rheumatoid arthritis susceptibility genes show pathotype-specific expression in synovial tissue of patients with early treatment-naïve RA
- Impact of disease activity on bone density, microarchitecture, and biomechanical properties in rheumatoid and psoriatic arthritis over 7 years
- Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries
- Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals
- Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial
- Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series
- High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis
- Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc)
- Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial